CTLA4 and melanoma: Patients with high m6Sig score exhibited significantly longer survival time (log-rank test, p = 0.0082, Figure 6E) and markedly clinical response to PD-1/CTLA-4 treatment in melanoma (response rate, high vs low m6Sig score subgroup, 52.3 vs 31.2%, Figure 6F).